StockData
Radiopharm Theranostics Ltd logo

Radiopharm Theranostics Ltd (RADX) stock

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30
$0.79−0.03 (-3.66%)

Close on Nov 12, 2026Market cap $9.33MP/E –Yield –

Radiopharm Theranostics Ltd saw revenue fall 23.8% to $2.77M over fiscal 2026. At the latest close the market valued the company at $9.33M.

Revenue
$2.77M
-23.8% vs. a year earlier
Operating income
-$56.78M
FY2026
EPS, diluted
-$1.79
FY2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026

Valuation

Market cap
$9.33M
P/E ratio
–
Price to sales
3.37
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$2.77M
EPS, diluted
-$1.79

Trading

Previous close
$0.82
Open
$0.80
Day's range
$0.74 – $0.80
Volume
32,970
Average volume (20 days)
49,838
Beta (5 years)
1.09
52-week range
$0.74 – $16.25
RSI (14 days)
32.1
Volatility (1 year)
170.5%
Relative volume
0.43×
WACC
10.4%

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodRADXS&P 500DifferenceRADX per yearS&P 500 per year
1 month-28.8%-2.7%−26.1 pts
3 months-71.6%-1.7%−69.8 pts
Year to date-84.9%+11.9%−96.8 pts
1 year-83.1%+12.0%−95.1 pts

Five years at a glance

Fiscal years 2022 to 2026, USD

Revenue

$2.77M-23.8% YoY

Gross profit

$263.39K+570.6% YoY

Operating income

-$56.78M

EPS, diluted

-$1.79

Free cash flow

–
Reported period

Press releases

Releases Radiopharm Theranostics filed with the SEC as exhibits to Form 8-K or 6-K

  1. CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
    6-K
  2. QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT
    6-K
  3. NOTICE OF ANNUAL GENERAL MEETING/PROXY FORM
    6-K
  4. RADIOPHARM RECEIVES $8M ADVANCE ON FY26 R&D TAX INCENTIVE
    6-K
  5. CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
    6-K
  6. NOTIFICATION REGARDING UNQUOTED SECURITIES - RAD
    6-K
All press releases and earnings

About Radiopharm Theranostics

Pharmaceutical Preparations

The provided text does not contain factual descriptions of the company's business activities, main commercial products, business segments, or customer base. The text consists almost entirely of XBRL metadata tags, accounting line tags, and a brief note regarding accrued receivables from the Australian Taxation Office. Consequently, specific information about operational segments, offerings, and customers is absent from the provided source.

Company profile, executives and history

Radiopharm Theranostics stock: common questions

What is Radiopharm Theranostics's stock price?

RADX closed at $0.79 on Nov 12, 2026, down 3.66% on the day. Over the past 52 weeks it traded between $0.74 and $16.25.

What is Radiopharm Theranostics's market cap?

Radiopharm Theranostics was worth $9.33M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

What is RADX's P/E ratio?

Radiopharm Theranostics lost money over fiscal 2026 (diluted EPS -$1.79), so it has no meaningful P/E ratio.

How much revenue does Radiopharm Theranostics make?

Radiopharm Theranostics reported revenue of $2.77M for fiscal 2026, down 23.8% from a year earlier.

Does Radiopharm Theranostics pay a dividend?

No. Radiopharm Theranostics has not paid a cash dividend over the last twelve months.

How has RADX stock performed over the past year?

Including dividends, RADX returned -83.1% over the past year, against +12.0% for the S&P 500.

Who are Radiopharm Theranostics's competitors?

Companies most similar to Radiopharm Theranostics by business, industry and size include PCT, TXMD, CLLS, OLOX, PTCHF.

See a number that looks wrong?